<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01563562</url>
  </required_header>
  <id_info>
    <org_study_id>402-C-1002</org_study_id>
    <nct_id>NCT01563562</nct_id>
  </id_info>
  <brief_title>Single-Dose, Open-Label Pharmacokinetic Study of Bardoxolone Methyl in Subjects With Mild, Moderate, and Severe Hepatic Impairment and Normal Hepatic Function</brief_title>
  <official_title>A Single-Dose, Open-Label Pharmacokinetic Study of Bardoxolone Methyl in Subjects With Mild, Moderate, and Severe Hepatic Impairment and Normal Hepatic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reata Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reata Pharmaceuticals, Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the pharmacokinetic profile of bardoxolone methyl&#xD;
      following a single oral dose of 20 mg bardoxolone methyl in subjects with mild, moderate, and&#xD;
      severe hepatic impairment, as compared to healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve</measure>
    <time_frame>0, 0.5,1, 2, 3, 4, 6, 9, 12, 18, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 216, 264, 312, and 360 hours following dose administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to maximum observed concentration</measure>
    <time_frame>0, 0.5,1, 2, 3, 4, 6, 9, 12, 18, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 216, 264, 312, and 360 hours following dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral clearance</measure>
    <time_frame>0, 0.5,1, 2, 3, 4, 6, 9, 12, 18, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 216, 264, 312, and 360 hours following dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life</measure>
    <time_frame>0, 0.5,1, 2, 3, 4, 6, 9, 12, 18, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 216, 264, 312, and 360 hours following dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal rate constant</measure>
    <time_frame>0, 0.5,1, 2, 3, 4, 6, 9, 12, 18, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 216, 264, 312, and 360 hours following dose administration</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Hepatic Impairment</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Bardoxolone Methyl 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bardoxolone Methyl</intervention_name>
    <description>Oral, Single dose</description>
    <arm_group_label>Bardoxolone Methyl 20 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All subjects&#xD;
&#xD;
               1. Male or female subjects between 18 and 70 years, inclusive; must meet all of the&#xD;
                  following criteria to be included in the study:&#xD;
&#xD;
               2. Willing to practice method of birth control (both males who have partners of&#xD;
                  childbearing potential and females of childbearing potential) during screening,&#xD;
                  while taking study drug and for at least 30 days after the last dose of study&#xD;
                  drug is ingested;&#xD;
&#xD;
               3. Female subjects of childbearing potential must be non-pregnant and non-lactating&#xD;
                  and have a negative serum pregnancy test result before enrollment into the study;&#xD;
&#xD;
               4. Body mass index (BMI) between 18 and 37 kg/m2;&#xD;
&#xD;
               5. Willing and able to give written informed consent for study participation;&#xD;
&#xD;
               6. Willing and able to cooperate with all aspects of the protocol.&#xD;
&#xD;
                  Subjects with hepatic impairment&#xD;
&#xD;
               7. Have documented evidence of hepatic cirrhosis by biopsy, nuclear scan, CT, MRI,&#xD;
                  ultrasound, or other clinically acceptable methods; must meet all of the&#xD;
                  following criteria to be included in the study:&#xD;
&#xD;
               8. Be classified as Child-Pugh class A (mild), B (moderate), or C (severe). (See&#xD;
                  Appendix A for Child-Pugh system.)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  All subjects&#xD;
&#xD;
               1. Participated in another clinical trial of an investigational drug (or a medical&#xD;
                  device) within 30 days of Study Day -1, or are currently participating in another&#xD;
                  trial of an investigational drug (or a medical device); with any of the following&#xD;
                  conditions or characteristics must be excluded from the study:&#xD;
&#xD;
               2. Known hypersensitivity to any component in the formulation of the study drug,&#xD;
                  bardoxolone methyl;&#xD;
&#xD;
               3. Any medical or dental procedure, no matter how minor, that is planned or&#xD;
                  anticipated to occur during the conduct of the study;&#xD;
&#xD;
               4. History of drug or alcohol abuse or dependence within the last year;&#xD;
&#xD;
               5. Donation or receipt of blood or blood components within the 4 weeks prior to&#xD;
                  Study Day -1. The investigator should instruct subjects who participate in this&#xD;
                  study not to donate blood or blood components for 4 weeks after the completion of&#xD;
                  the study;&#xD;
&#xD;
               6. Abnormal screening ECG which is interpreted by the investigator to be clinically&#xD;
                  significant;&#xD;
&#xD;
               7. A positive test for drug(s) of abuse (ethanol, amphetamines, benzodiazepines,&#xD;
                  barbiturates, cocaine, opiates, or cannabinoids) at the screening or the Day -1&#xD;
                  visit, unless the positive drug screen is for a subject with hepatic impairment&#xD;
                  for a prescription drug and is approved by the principal investigator;&#xD;
&#xD;
               8. Female subjects who are planning a pregnancy or are pregnant or lactating;&#xD;
&#xD;
               9. Deemed by the investigator to be inappropriate for this study, including subjects&#xD;
                  who are unable to communicate with the investigator due to language problems,&#xD;
                  poor mental development, or impaired cerebral function;&#xD;
&#xD;
              10. Any concurrent clinical conditions that in the judgment of the investigator could&#xD;
                  either potentially pose a health risk to the subject while involved in the study&#xD;
                  or could potentially influence the study outcome;&#xD;
&#xD;
              11. Positive test results for human immunodeficiency virus type 1 or 2 antibody at&#xD;
                  screening;&#xD;
&#xD;
              12. Have an estimated creatinine clearance &lt; 60 mL/min on Study Day -1 using the&#xD;
                  Cockcroft-Gault equation (Appendix B);&#xD;
&#xD;
              13. Any condition possibly affecting absorption, distribution, metabolism or&#xD;
                  excretion of drugs that may confound the analyses conducted in this study (for&#xD;
                  example: previous surgery on the gastrointestinal tract that includes removal of&#xD;
                  parts of stomach, bowel, liver, gall bladder, pancreas, venacaval shunts, or&#xD;
                  transjugular intrahepatic portosystemic shunts]).&#xD;
&#xD;
                  Subjects with hepatic impairment&#xD;
&#xD;
              14. Sustained systolic blood pressure &gt; 160 mmHg or &lt; 100 mmHg or a diastolic blood&#xD;
                  pressure &gt; 100 mmHg at screening or baseline measured after 5 minutes in a&#xD;
                  sitting position; who have any of the following conditions or characteristics&#xD;
                  must be excluded from the study:&#xD;
&#xD;
              15. A pulse rate at rest in a sitting position of &lt; 45 bpm or &gt; 105 bpm;&#xD;
&#xD;
              16. Documented evidence of primary biliary cirrhosis;&#xD;
&#xD;
              17. Evidence of recent (two months or less) or current gastrointestinal bleeding;&#xD;
&#xD;
              18. Platelet counts &lt;50,000 or &gt;450,000.&#xD;
&#xD;
                  Subjects with normal hepatic function&#xD;
&#xD;
              19. Sustained systolic blood pressure &gt; 150 mmHg or &lt; 100 mmHg or a diastolic blood&#xD;
                  pressure &gt; 95 mmHg at screening measured after 5 minutes in a sitting position;&#xD;
                  who have any of the following conditions or characteristics must be excluded from&#xD;
                  the study:&#xD;
&#xD;
              20. A pulse rate at rest in a sitting position of &lt; 45 bpm or &gt; 100 bpm;&#xD;
&#xD;
              21. Evidence or history of or concurrent clinically significant allergic (except for&#xD;
                  untreated, asymptomatic, seasonal allergies at time of dose administration),&#xD;
                  hematological, endocrine, immunological, renal, pulmonary, gastrointestinal,&#xD;
                  cardiovascular, hepatic, psychiatric, or neurological disease that in the&#xD;
                  judgment of the investigator could potentially either pose a health risk to the&#xD;
                  subject during the study or influence the study outcome;&#xD;
&#xD;
              22. Evidence of hepatic or biliary dysfunction including elevation of total&#xD;
                  bilirubin, direct bilirubin, aspartate aminotransferase (AST), alanine&#xD;
                  aminotransferase (ALT), gamma glutamyl transpeptidase (GGT), lactate&#xD;
                  dehydrogenase (LDH), or alkaline phosphatase levels to greater than the upper&#xD;
                  limit of normal (ULN);&#xD;
&#xD;
              23. Positive test results for hepatitis B virus antibody, or hepatitis C virus&#xD;
                  antibody at screening;&#xD;
&#xD;
              24. Use of or need for any systemic drug(s) including vitamins or herbal preparations&#xD;
                  other than drugs used for contraception, within 10 days before Study Day -1 or&#xD;
                  during the study;&#xD;
&#xD;
              25. Use of aspirin, non-steroidal anti-inflammatory agents, or acetaminophen within 5&#xD;
                  days prior to the ingestion of the study drug; use of aspirin or non-steroidal&#xD;
                  anti inflammatory agents (but not acetaminophen) will be allowed for isolated&#xD;
                  episodes of pain at the discretion of the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Miami School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>March 23, 2012</study_first_submitted>
  <study_first_submitted_qc>March 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2012</study_first_posted>
  <last_update_submitted>April 9, 2013</last_update_submitted>
  <last_update_submitted_qc>April 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

